Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Nordic nanovector_PhII_CD37_mAb_radionuclide_FL (Non-Hodgkin Lymphoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how different amounts of the study drug work on follicular lymphoma.
What is the Condition Being Studied?
Relapsed/Refractory Follicular Lymphoma

Who Can Participate in the Study?

Adults who:
-Have relapsed Follicular Lymphoma and have received 2 or more chemotherapy or immunotherapy based regimens.

Age Group

What is Involved?

If you choose to be in this study:
-You will be randomly assigned (like flipping a coin) to get either dose A or does B of the study drug Betalutin. The only difference in the groups is the amount of the study drug given.
-Receive one single dose of study drug as an injection into a vein
-Give a small blood sample once a week for 12 weeks
-Follow-up visits 3 to 6 months for up to 5 years
-CT/PET scans at some follow-up visits

Study Details

Full Title
A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide- conjugate for treatment of relapsed non-Hodgkin lymphoma.
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00101230
NCT: NCT01796171
Phase I/II
Contact the Duke Recruitment Innovation Center